Evidence map›Paper›PMID 33618745›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

CircAGAP1 promotes tumor progression by sponging miR-15-5p in clear cell renal cell carcinoma.

Qi Lv, Gangmin Wang, Yinan Zhang, Aijun Shen, Junjun Tang, Yi Sun, Chunhui Ma, Peijun Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Qi Lv *Department of Medical Imaging, Tongji Hospital, Tongji University School of Medicine, Xincun Road No. 389, Shanghai, China.
Gangmin Wang *Department of Urology, Huashan Hospital, Fudan University, Urumuqi Road No. 12, Shanghai, 200040, China.
Yinan ZhangDepartment of Urology, Shandong Provincial Hospital affiliated with Shandong University, Jingwuweiqi Road No. 324, Jinan, 250021, Shandong, China.
Aijun ShenDepartment of Medical Imaging, Tongji Hospital, Tongji University School of Medicine, Xincun Road No. 389, Shanghai, China.
Junjun TangDepartment of Medical Imaging, Tongji Hospital, Tongji University School of Medicine, Xincun Road No. 389, Shanghai, China.
Yi SunDepartment of Urology, No.971 Hospital of the PLA Navy, Qingdao, 266071, Shandong, China.
Chunhui MaDepartment of Orthopedics, Shanghai General Hospital of Shanghai Jiaotong University, Wujin Road No. 85, Shanghai, 200080, China. drmachunhui@163.com.
Peijun WangDepartment of Medical Imaging, Tongji Hospital, Tongji University School of Medicine, Xincun Road No. 389, Shanghai, China. 05810@tongji.edu.cn.
Tongji Hospital · CNHuashan Hospital · CNPeople's Liberation Army 401 Hospital · CNShandong University · CNShanghai First People's Hospital · CNTongji University · CN

Funding

National Natural Science Foundation of China 81771889National Natural Science Foundation of China 81830059National Natural Science Foundation of China 81974274
6 · The paper itself

Abstract

backgroundAccumulating evidence has revealed that circular RNAs (circRNAs), as novel noncoding RNAs, play critical roles in carcinogenesis and tumor progression. However, the functions and molecular mechanisms of circRNAs in clear cell renal cell carcinoma (ccRCC) are largely unknown.

methodsThe expression and functions of circAGAP1 were identified in clinical samples, ccRCC cells and in vivo animal models. The molecular mechanism of circAGAP1 was investigated by fluorescence in situ hybridization, RNA immunoprecipitation and luciferase assays.

resultscircAGAP1 (circ0058792) expression was significantly upregulated in ccRCC tissues compared to adjacent nontumor tissues. Moreover, the expression of circAGAP1 was closely related to the tumor size, nuclear grade and clinical stage of ccRCC in patients. Mechanistic studies demonstrated that cytoplasmic circAGAP1 targeted miR-15-5p in an RNA-induced silencing complex. Additionally, miR-15-5p expression was downregulated in ccRCC. Luciferase reporter assays showed that E2F transcription factor 3 (E2F3) was a target of miR-15-5p, and upregulated E2F3 expression was positively correlated with circAGAP1 in ccRCC. Furthermore, the tumor-promoting functions of circAGAP1 could be alleviated by miR-15-5p mimics in vitro and in vivo.

conclusionOur results clarify that circAGAP1 exerts its oncogenic functions as a competitive endogenous RNA (ceRNA) by sponging miR-15-5p, which promotes E2F3 expression. Targeting circAGAP1 might be a new attractive therapeutic strategy in ccRCC.

Indexed as

AnimalsApoptosisCarcinoma, Renal CellCell Line, TumorCell ProliferationDisease ProgressionDown-RegulationGTPase-Activating ProteinsMiceMice, NudeMicroRNAsRNA, CircularUp-RegulationAGAP1 protein, humanGTPase-Activating ProteinsMicroRNAsMIRN15 microRNA, humanRNA, CircularceRNAcircRNAClear cell renal carcinomaE2F3miR-15

Identifiers

PMID33618745
PMCPMC7901094
OpenAlexW3130125085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.